Continuing the expansion of its largest Regulatory Affairs hub globally, Teva announced the opening of a new state-of-the-art Research & Development facility in Mumbai, India. Additional plans include opening a first-of-its-kind clinic for bioequivalence studies in the same space as a bioanalytical laboratory.

Teva leadership, local officials and other key partners attended the grand opening to commemorate the occasion: “We’re pleased to complete the development of this world class facility for Teva Pharmaceuticals on one of the most unique and highly visible sites in Mumbai,” said Hafrun Fridriksdottir, EVP and Head of Global R&D, Teva Pharmaceuticals. “The unique onsite clinic will provide accommodations for patients, supporting our mission of going beyond medicine to develop innovative patient-centric treatments.”

The new R&D facility is located at the Seawoods multi-purpose complex, a prime destination and transit hub in Mumbai, India that will offer workspace for over 200 employees, including 100 new high-skill jobs. Teva looks forward to the new opportunities that this site will offer and is honored to be so graciously welcomed into the city of Mumbai.

“This is an exciting milestone for Teva’s Global R&D group and we are looking forward to establishing a presence in one of the top pharmaceutical innovation hubs in the world with access to world class talent,” said Michael Banks, SVP, Global Regulatory Affairs for Teva. “Not only will our site create new specialized jobs in the life sciences community, but also expand and advance our research and regulatory capabilities.”

This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our Privacy and Cookie Notice.